| HOME >> BIOLOGY >> TECHNOLOGY |
Stellant(R) CT Injection System Technology Detects Extravasations during CT
Contrast Injections
WARRENDALE, Pa., May 22 /PRNewswire/ -- MEDRAD, INC., announced today that its XDS(TM) Extravasation Detector has received a 2008 Medical Design Excellence Award(R) (MDEA). The XDS employs a technology that aids in the detection of leaking intravenous contrast media from the injection site into surrounding tissue during computed tomography (CT) diagnostic studies.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )
"This prestigious award recognizes our XDS Extravasation Detector technology, the investment of many resources for research and development, and the inherent risk of developing medical devices; the MDEA validates that the investment and risk were worth it," said Cliff Kress, senior vice president, MEDRAD CT Business Unit. "We are proud that we have succeeded in developing an extravasation technology that continues MEDRAD's long-standing commitment to patient safety."
The MDEA competition, presented by Canon Communications and sponsored by Medical Device & Diagnostic Industry Magazine, recognizes medical product excellence in design and engineering features, innovative use of materials, user-related functions that improve healthcare delivery, features that benefit patients, and the ability of the development team to overcome challenges. An impartial, multi-disciplinary panel of jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics reviewed the entries and selected the winners.
MEDRAD and development partner, Battelle Medical Device Solutions, will accept the award at a ceremony June 4 at the Medical Design & Manufacturing (MD&M) East 2008 Conference and Exposition in New York City.
More information on the XDS Extravasation Detector is avai
'/>"/>
| SOURCE MEDRAD, INC. Copyright©2008 PR Newswire. All rights reserved |